Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TTK | P33981 | 12/20 | 0.53 |
| ▸ | CA1 | P00915 | 3/20 | 0.46 |
| ▸ | CA2 | P00918 | 3/20 | 0.46 |
| ▸ | CA12 | O43570 | 2/20 | 0.46 |
| ▸ | CA9 | Q16790 | 2/20 | 0.46 |
| ▸ | ZAP70 | P43403 | 1/20 | 0.45 |
| ▸ | AURKA | O14965 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 2/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.40 |
| ▸ | NPC1 | O15118 | 1/20 | 0.40 |
| ▸ | NAMPT | P43490 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12409290 | 0.90 | TTK (0.46) | TTKCA2ZAP70 | |
| SCHEMBL12409267 | 0.87 | TTK (0.48) | TTKCA1CA2CA12CA9 | |
| SCHEMBL12409233 | 0.87 | TTK (0.53) | TTKCA1CA2CA12CA9 | |
| SCHEMBL2181894 | 0.87 | TTK (0.53) | TTKCA1CA2CA9ZAP70 | |
| SCHEMBL12409269 | 0.86 | TTK (0.52) | TTKCA1CA2CA12CA9 | |
| SCHEMBL12409231 | 0.85 | TTK (0.51) | TTKCA1CA2CA12CA9 | |
| SCHEMBL12409310 | 0.85 | TTK (0.57) | TTKCA1CA2CA12CA9 | |
| SCHEMBL12409228 | 0.84 | CA1 (0.52) | TTKCA1CA2CA12CA9 | |
| SCHEMBL3466302 | 0.84 | CA2 (0.52) | TTKCA1CA2CA12CA9 | |
| SCHEMBL12409303 | 0.83 | TTK (0.49) | TTKCA1CA2ZAP70MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8362018-B2 | Substituted imidazo[1,2-a]pyrazine compounds useful for the treatment of viral infections | BIOFOCUS DPI, LTD. (GB) | 2013-01-29 | — | — | US | disclosed |
| US-8362018-B2 | Substituted imidazo[1,2-a]pyrazine compounds useful for the treatment of viral infections | BIOFOCUS DPI, LTD. (GB) | 2013-01-29 | — | — | US | disclosed |
| US-20110166147-A1 | IMIDAZOPYRAZINE COMPOUNDS | BIOFOCUS DPI, LTD. (GB) | 2011-07-07 | — | — | US | disclosed |
| US-20110166147-A1 | IMIDAZOPYRAZINE COMPOUNDS | BIOFOCUS DPI, LTD. (GB) | 2011-07-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110166147-A1 | IMIDAZOPYRAZINE COMPOUNDS | CYP3A5, HAVCR2, CYP3A43 | TTK 3239/4885CA1 4484/4885CA2 4053/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.